[105-POS] : Clinical evaluation of placental growth factor (PlGF) for the management of suspected placental pathology in high-risk pregnancies

Introduction Recent data suggest placental growth factor (PlGF) has clinical utility for the management of suspected pre-eclampsia (PE) and/or fetal growth restriction (FGR). Objective To evaluate the added value of PlGF as a diagnostic test for placental dysfunction in a high-risk cohort. Methods High-risk women n  = 39; suspected FGR = 13, superimposed PE = 21, both = 4) had a PlGF measured using Alere Triage. The test was revealed and surveillance adjusted. Delivery decisions were made using standard clinical protocols and were not based on PlGF measurements. Test results were classified as normal (>100 pg/ml), low (12–100 pg/ml) or very low ( Results The median test to delivery interval was shorter with a low/very low vs normal PlGF; 11.5 vs 24 days ( p  = 0.02). Using the test nearest delivery, 11/39 had a very low PLGF; 10/11 delivered preterm ( 100 pg/ml measured 21 days prior to delivery. Conclusions In this small high-risk group, PlGF was useful in distinguishing superimposed pre-eclampsia from deterioration in chronic maternal disease (without features of placental dysfunction) but less discriminative for FGR in the absence of maternal disease. Disclosures E. Shawkat: None. E. Johnstone: None. D. Nice: None. A. Sayce: None. K. Hayden: None. J. Myers: None.